Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 44 points (-0.3%) at 15,515 as of Monday, July 29, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 829 issues advancing vs. 2,095 declining with 99 unchanged. The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Haemonetics Corporation ( HAE), down 8.7%, Perrigo Company ( PRGO), down 6.7%, Dr. Reddy Laboratories ( RDY), down 3.3%, Alexion Pharmaceuticals ( ALXN), down 2.6% and Teva Pharmaceutical Industries ( TEVA), down 2.3%. Top gainers within the sector include Alkermes ( ALKS), up 5.3%, Shire ( SHPG), up 1.2% and WellPoint ( WLP), up 1.2%. TheStreet would like to highlight 5 stocks pushing the sector lower today: 5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biogen Idec is down $5.18 (-2.3%) to $218.05 on average volume. Thus far, 640,720 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $217.01-$224.11 after having opened the day at $221.86 as compared to the previous trading day's close of $223.23. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $54.0 billion and is part of the drugs industry. Shares are up 55.4% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, solid stock price performance and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.